Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 110.05B |
| Revenue (ttm) | 45.93B |
| Net Income (ttm) | 9.11B |
| Shares Out | 1.22B |
| EPS (ttm) | 7.39 |
| PE Ratio | 17.33 |
| Forward PE | 10.97 |
| Dividend | 3.92 (4.35%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 1,560,576 |
| Average Volume | 1,615,451 |
| Open | 90.13 |
| Previous Close | 90.13 |
| Day's Range | 89.24 - 90.79 |
| 52-Week Range | 76.15 - 110.88 |
| Beta | 0.37 |
| RSI | 67.93 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Merck (MRK) and Sanofi Await CDC's Hepatitis B Vaccine Decision
Merck (MRK) and Sanofi Await CDC's Hepatitis B Vaccine Decision
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates Prioritized later-stage preclinical pipeline including wholly-ow...
The Zacks Analyst Blog Accenture, Sanofi and Dell
Zacks spotlights fresh research on Accenture, Sanofi, and Dell Technologies, revealing trends in consulting, pharma, and AI-driven tech growth
Top Research Reports for Accenture, Sanofi & Dell Technologies
Accenture, Sanofi, and Dell Technologies stand out in today's top analyst research picks, each navigating growth and market pressures in distinct ways.
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.
REGN: Regeneron and Sanofi Report Positive Dupixent Trial Results
REGN: Regeneron and Sanofi Report Positive Dupixent Trial Results
Regeneron and Sanofi's Dupixent succeeds in late-stage study
Sanofi And Regeneron's Dupixent Meets Primary Goal In Phase 3 Allergic Fungal Rhinosinusitis Study
(RTTNews) - Sanofi SA (SNY) on Friday announced that the pivotal LIBERTY-AFRS-AIMS phase 3 study of Dupixent, co-developed with Regeneron Pharmaceuticals Inc. (REGN), for the treatment of individuals ...
Sanofi (SNY) Shares Encouraging Phase 3 Results for Dupixent in AFRS Patients
Sanofi (SNY) Shares Encouraging Phase 3 Results for Dupixent in AFRS Patients
Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase...
Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Novavax Completes Marketing Authorization Transfers For Nuvaxovid To Sanofi
(RTTNews) - Novavax (NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid to Sanofi (SNY), enabling Sanofi to take full responsibility for commercia...
Sanofi extends agreement with Medidata on clinical trials
Medidata And Sanofi Expand Collaboration To Advance Clinical Research Innovation
(RTTNews) - Medidata, a Dassault Systèmes brand and a leading provider of clinical trial solutions for the life sciences industry, announced an extension of its strategic partnership with Sanofi. Unde...
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care Expanded 10-plus-year collaboration will levera...
Sanofi Breaks Above 200-Day Moving Average - Bullish for SNY
In trading on Friday, shares of Sanofi (Symbol: SNY) crossed above their 200 day moving average of $51.00, changing hands as high as $52.20 per share. Sanofi shares are currently trading up about 4.7%...
Sanofi SA (SNY) Q3 2025 Earnings Call Highlights: Strong Growth Driven by DUPIXENT and New Launches
Sanofi SA (SNY) Q3 2025 Earnings Call Highlights: Strong Growth Driven by DUPIXENT and New Launches
Sanofi: Is Dupixent Too Successful?
Q3 2025 Sanofi SA Earnings Call Transcript
Q3 2025 Sanofi SA Earnings Call Transcript
Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal
Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript
Sanofi 2025 Q3 - Results - Earnings Call Presentation
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark
Sanofi SA (NASDAQ: SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion . Sales increased 2.3% year over year, up 7% in constant currency...
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark
Sanofi SA (NASDAQ:SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion. Sales increased 2.3% year over year, up 7% in constant currency.
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.